CSL Behring has appointed a contract manufacturer for its products. In July 2024, following the Lexington Transaction involving uniQure Inc., uniQure biopharma B.V., Genezen Holdings Inc., and Genezen MA, Inc., the manufacturing and supply of CSL Behring's commercial demand for HEMGENIX were transferred to Genezen. Genezen now manufactures and supplies HEMGENIX on behalf of CSL Behring.
Uniqure N V's Comment on Supply Chain
CSL Behring has appointed a contract manufacturer for its products. In July 2024, following the Lexington Transaction involving uniQure Inc., uniQure biopharma B.V., Genezen Holdings Inc., and Genezen MA, Inc., the manufacturing and supply of CSL Behring's commercial demand for HEMGENIX were transferred to Genezen. Genezen now manufactures and supplies HEMGENIX on behalf of CSL Behring.
Sources:
Uniqure N v 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Uniqure N v ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
